Preprint: Serious Adverse Events of Special Interest Following mRNA Vaccination in Randomized Trials

Coronavirus, Deaths, Health, Hospitalization, Moderna, Pfizer/Biontech, Revaccination, Vaccine, Vaccine Waning

“The excess risk of serious adverse events of special interest surpassed the risk reduction for COVID-19 hospitalization relative to the placebo group in both Pfizer and Moderna trials.”.

Results: Pfizer and Moderna mRNA COVID-19 vaccines were associated with an increased risk of serious adverse events of special interest, with an absolute risk increase of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95% CI -0.4 to 20.6 and -3.6 to 33.8), respectively. Combined, the mRNA vaccines were associated with an absolute risk increase of serious adverse events of special interest of 12.5 per 10,000 (95% CI 2.1 to 22.9).

The excess risk of serious adverse events of special interest surpassed the risk reduction for COVID-19 hospitalization relative to the placebo group in both Pfizer and Moderna trials (2.3 and 6.4 per 10,000 participants, respectively).

Preprint: Serious Adverse Events of Special Interest Following mRNA Vaccination in Randomized Trials

 

Preprint discussed in some detail in this GB News segment:

 

 

 

A regional director who was employed at the research organisation Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial. Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding. After repeatedly notifying Ventavia of these problems, the regional director, Brook Jackson, emailed a complaint to the US Food and Drug Administration (FDA). Ventavia fired her later the same day. Jackson has provided The BMJ with dozens of internal company documents, photos, audio recordings, and emails.

BMJ: Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial

 

 

Preprint: Tunneling nanotubes provide a route for SARS-CoV-2 spreading

 

 

 

 

 

Image CD2-Promotes-Human-Natural-Killer-Cell-Membrane-Nanotube-Formation-pone
courtesy of Comerci C, Mace E, Banerjee P, Orange J, CC BY 2.5, via Wikimedia Commons